Literature DB >> 10945071

Aims, outcome measures, study sites and patient sample. EPSILON Study 1. European Psychiatric Services: Inputs Linked to Outcome Domains and Needs.

T Becker1, M Knapp, H C Knudsen, A H Schene, M Tansella, G Thornicroft, J L Vázquez-Barquero.   

Abstract

BACKGROUND: Cross-national research into the care of people with severe mental illnesses is hampered by a lack of standardised measures. The European Psychiatric Services: Inputs Linked to Outcome Domains and Needs (EPSILON) Study is a European Union funded project within the BIOMED-2 programme. The project aims to develop standardised instruments to facilitate future cross-national research. AIMS: To describe the aims, outcome measures, study sites and patient samples of the EPSILON Study. METHOD, RESULTS,
CONCLUSIONS: See companion papers in this supplement.

Entities:  

Mesh:

Year:  2000        PMID: 10945071     DOI: 10.1192/bjp.177.39.s1

Source DB:  PubMed          Journal:  Br J Psychiatry Suppl        ISSN: 0960-5371


  10 in total

1.  Correlates of quality of life in an Arab schizophrenia sample.

Authors:  Muhammad Ajmal Zahid; J U Ohaeri; A S Elshazly; M A Basiouny; H M Hamoda; R Varghese
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2009-09-02       Impact factor: 4.328

2.  Patient-centered care in affective, non-affective, and schizoaffective groups: patients' opinions and attitudes.

Authors:  Raymond Tempier; Shelanne L Hepp; C Randy Duncan; Betty Rohr; Krystal Hachey; Karen Mosier
Journal:  Community Ment Health J       Date:  2010-05-18

3.  Needs and quality of life among patients with schizophrenia in five European centres: what is the impact of global functioning scores?

Authors:  Thomas Becker; Morven Leese; Silvia Krumm; Mirella Ruggeri; José Luis Vázquez-Barquero
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2005-08-17       Impact factor: 4.328

4.  Inter-rater reliability of the Brief Psychiatric Rating Scale and the Groningen Social Disabilities Schedule in a European multi-site randomized controlled trial on the effectiveness of acute psychiatric day hospitals.

Authors:  Matthias Schützwohl; Joanna Jarosz-Nowak; Jane Briscoe; Krzysztof Szajowski; Thomas Kallert
Journal:  Int J Methods Psychiatr Res       Date:  2003       Impact factor: 4.035

5.  Relationship of family caregiver burden with quality of care and psychopathology in a sample of Arab subjects with schizophrenia.

Authors:  Muhammad A Zahid; Jude U Ohaeri
Journal:  BMC Psychiatry       Date:  2010-09-10       Impact factor: 3.630

6.  Predictors of general quality of life and the mediating role of health related quality of life in patients with schizophrenia.

Authors:  Carin J Meijer; Maarten W J Koeter; Mirjam A G Sprangers; Aart H Schene
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2008-10-30       Impact factor: 4.328

7.  Factors associated with hospital service satisfaction in a sample of Arab subjects with schizophrenia.

Authors:  Muhammad A Zahid; Jude U Ohaeri; Adel A Al-Zayed
Journal:  BMC Health Serv Res       Date:  2010-10-27       Impact factor: 2.655

8.  Caregiving in severe mental illness: the psychometric properties of the Involvement Evaluation Questionnaire in Portugal.

Authors:  Manuel Gonçalves-Pereira; Bob van Wijngaarden; Miguel Xavier; Ana L Papoila; José M Caldas-de-Almeida; Aart H Schene
Journal:  Ann Gen Psychiatry       Date:  2012-03-28       Impact factor: 3.455

9.  Determinants of patient satisfaction with hospital health care in psychiatry: results based on the SATISPSY-22 questionnaire.

Authors:  Xavier Y Zendjidjian; Pascal Auquier; Christophe Lançon; Anderson Loundou; Nathalie Parola; Melanie Faugère; Laurent Boyer
Journal:  Patient Prefer Adherence       Date:  2014-10-24       Impact factor: 2.711

10.  High Functioning Autism Spectrum Disorders in Adults: Consequences for Primary Caregivers Compared to Schizophrenia and Depression.

Authors:  Inge A C Grootscholten; Bob van Wijngaarden; Cornelis C Kan
Journal:  J Autism Dev Disord       Date:  2018-06
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.